Big pharma shied away from gene therapy for years. Academia picked up the slack

When big pharma backed away from gene therapy, academia transformed tech transfer to advance the science.

“The old way is, ‘I have a patent, I’m going to throw it over the fence to you and you throw me a sack of money,'” said John Swartley, managing director of the University of Pennsylvania’s Penn Center for Innovation, in an interview. “This is completely different. This is co-development.”


Skip to content